(Q37825016)

23 August 2017

1 reference

title

Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

23 August 2017

0 references

0 references

1 reference

1 reference

4

Tommaso Stroffolini

1 reference

23 August 2017

Antonio Rispo

3

1 reference

ORCID Public Data File 2021

author name string

Filomena Morisco

1

1 reference

23 August 2017

Fabiana Castiglione

2

1 reference

23 August 2017

Roberto Vitale

5

1 reference

23 August 2017

Stefano Sansone

6

1 reference

23 August 2017

Rocco Granata

7

1 reference

23 August 2017

Ambrogio Orlando

8

1 reference

23 August 2017

Riccardo Marmo

9

1 reference

23 August 2017

Gabriele Riegler

10

1 reference

23 August 2017

Maurizio Vecchi

11

1 reference

23 August 2017

Livia Biancone

12

1 reference

23 August 2017

Nicola Caporaso

13

1 reference

23 August 2017

language of work or name

1 reference

1 January 2011

1 reference

Digestive and Liver Disease

23 August 2017

1 reference

23 August 2017

43 Suppl 1

1 reference

23 August 2017

S40-8

1 reference

Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.

23 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Treatment of hepatitis B in special patient groups: hemodialysis, heart and renal transplant, fulminant hepatitis, hepatitis B virus reactivation.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Hepatitis B and C virus infection in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Occult hepatitis B and infliximab-induced HBV reactivation

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: a 4-year experience.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

1 reference

7 January 2021

European evidence-based Consensus on the management of ulcerative colitis: Current management

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Methotrexate for maintenance of remission in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Infliximab, azathioprine, or combination therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

The potential for disease modification in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Prophylaxis and treatment of hepatitis B in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Endemic hepatitis C virus infection in a Sicilian town: further evidence for iatrogenic transmission

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Declining prevalence of hepatitis B virus infection in Catalonia (Spain) 12 years after the introduction of universal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Factors affecting the compliance of the antenatal hepatitis B screening programme in Italy

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Evolving clinical landscape of chronic hepatitis B: A multicenter Italian study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Prevalence and Factors Related to Hepatitis B and C in Inflammatory Bowel Disease Patients in Spain: A Nationwide, Multicenter Study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Hepatitis B virus prevalence and transmission risk factors in inflammatory bowel disease patients at Clementino Fraga Filho university hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohnʼs disease patient

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

A comparison of hepatitis B seroepidemiology in ten European countries.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

1 reference

7 January 2021

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960691-3

7 January 2021

10.1016/S1590-8658(10)60691-3

Identifiers

DOI

1 reference

23 August 2017

1 reference